A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Parallel-group Clinical Trial to Assess the Effects of Teduglutide on Gastric Emptying of Liquids in Healthy Subjects

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2014 Feb 13

PMID 24517114

Citations 4

Authors

Jolene Kay Berg

Eric H Kim

Benjamin Li

Bo Joelsson

Nader N Youssef

Affiliations

Soon will be listed here.

Abstract

Background: Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-dependent delay in gastric emptying. The primary objective of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy subjects, as measured by the pharmacokinetics of acetaminophen.

Methods: This double-blind, parallel-group, single-center study enrolled and randomized 36 healthy subjects (22 men, 14 women) to receive subcutaneous doses of teduglutide 4 mg or placebo (2:1 ratio; 23:13) once daily on Days 1 through 10 in the morning. Gastric emptying of a mixed nutrient liquid meal was assessed by measuring acetaminophen levels predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 3.5, 4, 5, 6, 8, 10, 12, and 14 hours after administration of 1000 mg acetaminophen on Days 0 and 10. The primary study endpoint was a pharmacokinetic analysis of acetaminophen absorption in subjects receiving teduglutide or placebo.

Results: No significant differences in gastric emptying of liquids (acetaminophen area under the concentration [AUC] vs time curve from time 0 to the last measurable concentration, AUC extrapolated to infinity, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subjects receiving teduglutide 4 mg versus subjects receiving placebo. There were no serious adverse events (AEs), deaths, or discontinuations due to an AE reported during the study.

Conclusions: Teduglutide 4 mg/day for 10 days does not affect gastric emptying of liquids in healthy subjects as measured by acetaminophen pharmacokinetics. No unexpected safety signals were observed.

Trial Registration: This study was registered at ClinicalTrials.gov, identifier NCT01209351.

Citing Articles

GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats.

Maruta K, Takajo T, Akiba Y, Said H, Irie E, Kato I Dig Dis Sci. 2020; 65(9):2605-2618.

PMID: 32006214 PMC: 7392813. DOI: 10.1007/s10620-020-06097-6.

Gastrointestinal hormones and regulation of gastric emptying.

Camilleri M Curr Opin Endocrinol Diabetes Obes. 2018; 26(1):3-10.

PMID: 30418188 PMC: 6615897. DOI: 10.1097/MED.0000000000000448.

Teduglutide: A Review in Short Bowel Syndrome.

Kim E, Keam S Drugs. 2017; 77(3):345-352.

PMID: 28194723 DOI: 10.1007/s40265-017-0703-7.

Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Kochar B, Long M, Shelton E, Young L, Farraye F, Yajnik V J Clin Gastroenterol. 2016; 51(6):508-511.

PMID: 27433811 PMC: 5243925. DOI: 10.1097/MCG.0000000000000604.

References

Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C . Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008; 294(5):E846-52. DOI: 10.1152/ajpendo.00030.2008. View

Marier J, Beliveau M, Mouksassi M, Shaw P, Cyran J, Kesavan J . Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008; 48(11):1289-99. DOI: 10.1177/0091270008320605. View

JONDERKO G, Jonderko K, GOLAB T . Effect of glucagon on gastric emptying and on postprandial gastrin and insulin release in man. Mater Med Pol. 1989; 21(2):92-6. View

Drucker D, Asa S . Glucagon gene expression in vertebrate brain. J Biol Chem. 1988; 263(27):13475-8. View

Anvari M, Paterson C, Daniel E, McDonald T . Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci. 1998; 43(6):1133-40. DOI: 10.1023/a:1018863716749. View

Edwards C, Stanley S, Davis R, Brynes A, Frost G, Seal L . Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281(1):E155-61. DOI: 10.1152/ajpendo.2001.281.1.E155. View

Tolessa T, Gutniak M, Holst J, Efendic S, Hellstrom P . Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998; 43(10):2284-90. DOI: 10.1023/a:1026678925120. View

Kato Y, Yu D, Schwartz M . Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg. 1999; 34(1):18-20; discussion 20-1. DOI: 10.1016/s0022-3468(99)90221-x. View

Sorensen L, Flint A, Raben A, Hartmann B, Holst J, Astrup A . No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord. 2003; 27(4):450-6. DOI: 10.1038/sj.ijo.0802247. View

10.

Schmidt W, Siegel E, Creutzfeldt W . Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985; 28(9):704-7. DOI: 10.1007/BF00291980. View

11.

Xiao Q, Boushey R, Drucker D, Brubaker P . Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology. 1999; 117(1):99-105. DOI: 10.1016/s0016-5085(99)70555-x. View

12.

Rotondo A, Amato A, Lentini L, Baldassano S, Mule F . Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides. 2010; 32(1):60-4. DOI: 10.1016/j.peptides.2010.09.028. View

13.

Henriksen D, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Bone H . Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009; 45(5):833-42. DOI: 10.1016/j.bone.2009.07.008. View

14.

Benjamin M, McKay D, Yang P, Cameron H, Perdue M . Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000; 47(1):112-9. PMC: 1727982. DOI: 10.1136/gut.47.1.112. View

15.

Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom P . Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998; 68(3):525-30. DOI: 10.1093/ajcn/68.3.525. View

16.

OKeefe S, Jeppesen P, Gilroy R, Pertkiewicz M, Allard J, Messing B . Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013; 11(7):815-23.e1-3. DOI: 10.1016/j.cgh.2012.12.029. View

17.

Fehmann H, Habener J . Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992; 130(1):159-66. DOI: 10.1210/endo.130.1.1309325. View

18.

Jeppesen P, Hartmann B, Hansen B, Thulesen J, Holst J, Mortensen P . Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut. 1999; 45(4):559-63. PMC: 1727702. DOI: 10.1136/gut.45.4.559. View

19.

Miners J, Attwood J, Birkett D . Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol. 1983; 16(5):503-9. PMC: 1428054. DOI: 10.1111/j.1365-2125.1983.tb02207.x. View

20.

Jeppesen P, Sanguinetti E, Buchman A, Howard L, Scolapio J, Ziegler T . Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005; 54(9):1224-31. PMC: 1774653. DOI: 10.1136/gut.2004.061440. View